Drugs / MB310
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06582264 | Sep 2024 → Jan 2026 | ulcerative colitis | Microbiotica Ltd | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MB310 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06582264 ↗ |
| Modality | Other / unclassified | “Live bacterial therapeutic for oral administration” NCT06582264 ↗ |
| Route | Oral | “Live bacterial therapeutic for oral administration” NCT06582264 ↗ |